NASDAQ : NNNN
Anbio Biotechnology — Financial statements
Healthcare · Medical Instruments & Supplies · Germany
Last price 3.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 163.28M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Anbio Biotechnology (NNNN) reported revenue of 8.65M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 8.65M | 8.65M | 8.19M | 6.71M | 23.54M | 4.43M |
| Cost of Revenue | 1.10M | 1.10M | 2.30M | 3.35M | 10.98M | 1.89M |
| Gross Profit | 7.54M | 7.54M | 5.89M | 3.36M | 12.56M | 2.54M |
| Selling, General & Admin | 1.57M | 1.57M | 3.44M | 1.27M | 2.17M | 86.09K |
| Research & Development | 201.31K | 201.31K | 454.23K | 134.70K | 200.00K | |
| Operating Expenses | 1.78M | 1.78M | 3.89M | 1.40M | 2.37M | 86.09K |
| Operating Income | 5.77M | 5.77M | 2.00M | 1.96M | 10.20M | 2.46M |
| Interest Expense | -8.00K | |||||
| Interest & Investment Income | 210.03K | 210.03K | 337.51K | 165.34K | 42.24K | |
| Currency Exchange Gain (Loss) | 493.56K | 493.56K | 20.47K | 119.42K | -262.22K | -65.00 |
| Other Non Operating Income (Expenses) | 138.00 | 138.00 | 19.50K | 8.03K | 43.56K | 80.00K |
| EBT Excluding Unusual Items | 6.47M | 6.47M | 2.37M | 2.25M | 10.01M | 2.54M |
| Gain (Loss) on Sale of Investments | -68.00K | -68.00K | ||||
| Pretax Income | 6.40M | 6.40M | 2.37M | 2.25M | 10.01M | 2.54M |
| Net Income | 6.40M | 6.40M | 2.37M | 2.25M | 10.01M | 2.54M |
| Net Income to Common | 6.40M | 6.40M | 2.37M | 2.25M | 10.01M | 2.54M |
| Shares Outstanding (Basic) | 43.67M | 43.67M | 42.29M | 21.44M | ||
| Shares Outstanding (Diluted) | 43.67M | 43.67M | 42.29M | 21.44M | ||
| EPS (Basic) | 0.15 | 0.15 | 0.06 | 0.11 | ||
| EPS (Diluted) | 0.15 | 0.15 | 0.06 | 0.11 | ||
| Gross Margin | 87.24% | 87.24% | 71.90% | 50.07% | 53.36% | 57.40% |
| Operating Margin | 66.70% | 66.70% | 24.38% | 29.22% | 43.30% | 55.46% |
| Profit Margin | 74.06% | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| EBIT | 5.77M | 5.77M | 2.00M | 1.96M | 10.20M | 2.46M |
| EBIT Margin | 66.70% | 66.70% | 24.38% | 29.22% | 43.30% | 55.46% |
| Revenue as Reported | 8.65M | 8.65M | 8.19M | 6.71M | 23.54M | 4.43M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 7.77M | 7.77M | 11.76M | 9.69M | 7.10M | 4.18M |
| Short-Term Investments | 4.13M | 4.13M | 1.57M | |||
| Cash & Short-Term Investments | 11.90M | 11.90M | 11.76M | 9.69M | 8.67M | 4.18M |
| Accounts Receivable | 3.66M | 3.66M | 1.06M | 1.88M | 717.50K | |
| Other Receivables | 948.00 | 948.00 | ||||
| Receivables | 3.66M | 3.66M | 1.06M | 1.88M | 717.50K | |
| Inventory | 353.87K | |||||
| Prepaid Expenses | 14.68M | 14.68M | 5.71M | 4.17M | 4.92M | 15.56K |
| Other Current Assets | 1.29K | 3.26K | 4.88K | 1.29K | ||
| Total Current Assets | 30.24M | 30.24M | 18.53M | 15.75M | 13.94M | 4.92M |
| Property, Plant & Equipment | 12.06K | |||||
| Long-Term Deferred Charges | 387.44K | 42.84K | ||||
| Other Long-Term Assets | 19.30K | 2.99K | ||||
| Total Assets | 30.24M | 30.24M | 18.92M | 15.81M | 13.96M | 4.92M |
| Accounts Payable | 1.63M | 827.15K | 1.41M | 1.89M | ||
| Accrued Expenses | 130.97K | |||||
| Other Current Liabilities | 87.84K | 87.84K | 104.98K | 34.94K | 3.24K | 490.00K |
| Total Current Liabilities | 87.84K | 87.84K | 1.73M | 993.06K | 1.41M | 2.38M |
| Total Liabilities | 87.84K | 87.84K | 1.73M | 993.06K | 1.41M | 2.38M |
| Common Stock | 14.39K | 14.39K | 14.23K | 14.23K | ||
| Additional Paid-In Capital | 6.56M | 6.56M | 3.78K | 3.78K | ||
| Retained Earnings | 23.58M | 23.58M | 17.17M | 14.80M | 12.55M | 2.54M |
| Shareholders' Equity | 30.16M | 30.16M | 17.19M | 14.82M | 12.55M | 2.54M |
| Total Liabilities & Equity | 30.24M | 30.24M | 18.92M | 15.81M | 13.96M | 4.92M |
| Net Cash (Debt) | 11.90M | 11.90M | 11.76M | 9.69M | 8.67M | 4.18M |
| Net Cash Per Share | 0.27 | 0.27 | 0.28 | 0.45 | ||
| Filing Date Shares Outstanding | 43.89M | 43.89M | 43.89M | 42.29M | ||
| Total Common Shares Outstanding | 43.89M | 43.89M | 42.29M | 42.29M | ||
| Working Capital | 30.16M | 30.16M | 16.80M | 14.76M | 12.53M | 2.54M |
| Book Value Per Share | 0.69 | 0.69 | 0.41 | 0.35 | ||
| Tangible Book Value | 30.16M | 30.16M | 17.19M | 14.82M | 12.55M | 2.54M |
| Tangible Book Value Per Share | 0.69 | 0.69 | 0.41 | 0.35 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | 6.40M | 6.40M | 2.37M | 2.25M | 10.01M | 2.54M |
| Depreciation & Amortization | 12.06K | 6.25K | ||||
| Loss (Gain) From Sale of Investments | 68.00K | 68.00K | -337.10K | -163.39K | -38.88K | |
| Change in Accounts Receivable | -2.59M | -2.59M | 820.17K | -1.88M | 717.50K | -717.50K |
| Change in Inventory | 353.87K | -353.87K | ||||
| Change in Accounts Payable | -1.63M | -1.63M | 798.10K | -580.89K | -481.82K | 1.89M |
| Change in Other Net Operating Assets | -8.99M | -8.99M | -1.57M | 907.97K | -5.41M | 473.15K |
| Operating Cash Flow | -6.74M | -6.74M | 2.08M | 898.37K | 4.45M | 4.18M |
| Investment in Securities | -4.20M | -4.20M | 337.10K | 1.73M | -1.53M | |
| Investing Cash Flow | -4.20M | -4.20M | 337.10K | 1.73M | -1.53M | |
| Issuance of Common Stock | 7.23M | 7.23M | ||||
| Other Financing Activities | -282.55K | -282.55K | -344.61K | -42.84K | ||
| Financing Cash Flow | 6.95M | 6.95M | -344.61K | -42.84K | ||
| Net Cash Flow | -3.99M | -3.99M | 2.07M | 2.59M | 2.92M | 4.18M |
| Levered Free Cash Flow | -9.61M | -9.61M | 1.27M | 31.93K | 865.10K | |
| Unlevered Free Cash Flow | -9.61M | -9.61M | 1.27M | 31.93K | 870.10K | |
| Change in Working Capital | -13.21M | -13.21M | 44.65K | -1.20M | -5.53M | 1.65M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 155.38M | 1.32B | ||||
| Enterprise Value | 143.48M | 1.31B | ||||
| Last Close Price | 3.36 | 30.07 | ||||
| PE Ratio | 24.14 | 206.11 | ||||
| PS Ratio | 17.06 | 152.63 | ||||
| PB Ratio | 4.89 | 43.77 | ||||
| P/TBV Ratio | 4.89 | 43.77 | ||||
| EV/Sales Ratio | 15.68 | 151.08 | ||||
| EV/EBIT Ratio | 23.51 | 226.50 | ||||
| Net Debt / Equity Ratio | -0.40 | -0.40 | -0.68 | -0.65 | -0.69 | -1.65 |
| Asset Turnover | 0.35 | 0.35 | 0.47 | 0.45 | 2.50 | |
| Quick Ratio | 177.13 | 177.13 | 7.41 | 11.65 | 6.14 | 2.06 |
| Current Ratio | 344.31 | 344.31 | 10.71 | 15.86 | 9.88 | 2.07 |
| Return on Equity (ROE) | 27.05% | 27.05% | 14.83% | 16.47% | 132.75% | |
| Return on Assets (ROA) | 14.66% | 14.66% | 7.18% | 8.23% | 67.52% | |
| Return on Capital Employed (ROCE) | 19.10% | 19.10% | 11.60% | 13.20% | 81.30% | 96.80% |
| Earnings Yield | 4.14% | 0.48% | ||||
| Buyback Yield / Dilution | -3.26% | -3.26% | -97.30% |